CARL (Carlsmed) Total Stockholders Equity: $84.25 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CARL Carlsmed Inc CARL
12 GF Score
Price $14.76
! 1 Warning Sign
View Full Analysis

What is Carlsmed Total Stockholders Equity?

Carlsmed CARL -1.50% 12 Total Stockholders Equity is $84.25 Mil as of Jun. 2026. GuruFocus rates CARL with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Carlsmed's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $84.25 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Carlsmed's Book Value per Share for the quarter that ended in Jun. 2026 was $3.09. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Carlsmed's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.26.


Carlsmed  (NAS:CARL) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Carlsmed's Book Value per Share for the quarter that ended in Jun. 2026 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Carlsmed's Debt-to-Equity for the quarter that ended in Jun. 2026 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Carlsmed Total Stockholders Equity Related Terms


Carlsmed Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Carlsmed's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carlsmed Total Stockholders Equity Chart

Carlsmed Annual Data
Trend Dec23 Dec24 Dec25
Total Stockholders Equity
-46.13 -70.63 98.87

Carlsmed Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -83.07 106.66 98.87 92.25 84.25
CARL
12GF Score
Carlsmed Inc CARL
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $84.25 Mil mean?
Carlsmed (CARL) has a Total Stockholders Equity of $84.25 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Carlsmed and its competitors.
Is Carlsmed's Total Stockholders Equity too high?
Carlsmed's current Total Stockholders Equity is $84.25 Mil. Overall, Carlsmed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Carlsmed's Total Stockholders Equity compare to NRC and EVH?
Carlsmed's Total Stockholders Equity of $84.25 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Healthcare Providers & Services company?
A good Total Stockholders Equity depends on the Healthcare Providers & Services industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Carlsmed and its competitors. Carlsmed's current Total Stockholders Equity is $84.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carlsmed stock overvalued right now?
Carlsmed (CARL) has a current Total Stockholders Equity of $84.25 Mil. The current Total Stockholders Equity is $84.25 Mil. Carlsmed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Carlsmed (CARL), the current Total Stockholders Equity is $84.25 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Carlsmed Business Description

Other Exchanges I82:Germany
Address 1800 Aston Avenue, Suite 100, Carlsbad, CA, USA, 92008
Carlsmed Inc is a commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. The company operates as a single operating and reportable segment engaged in the design, manufacture, and marketing of its Aprevo technology platform, which provides customized surgical planning and implants for lumbar and cervical spine fusion procedures, mainly sold to hospitals and ambulatory surgical centers.
12GF Score

Get the complete analysis for CARL

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.76
Price